Delivery Order SPE2DB22D2206-SPE2DB25FHW90
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30, with a ceiling value of $23,438.54. This is a firm fixed price delivery order with no set-aside designation, completed through open competition. The order is scheduled for ultimate completion by September 2, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count packaging) with a ceiling value of $25,134.02. This firm fixed-price delivery order, which is not set-aside, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be performed and delivered from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $8,962.67 under a firm fixed price structure, with an ultimate completion date of August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $18,664.07 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count units) with a completion date of September 11, 2025. This competitive award, issued as a firm fixed-price delivery order with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with the agency. The pharmaceutical product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a ceiling value of $5,252.73. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $2,931.30 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count). The contract, which is of the firm fixed-price delivery order type with no set-aside designation, represents a competitive award to the pharmaceutical distributor. Performance of this order is scheduled for completion by July 15, 2025, and will be executed at the awardee's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $14,466.96 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHW90Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30 units. This order, valued at $14,531.95, represents a competitive firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. Ondansetron is a widely-used antiemetic medication commonly prescribed to manage nausea and vomiting in military healthcare and federal medical supply chains. The delivery order has an ultimate completion date of July 15, 2025, reflecting the time-sensitive nature of pharmaceutical procurement for federal medical operations. AmerisourceBergen's substantial IDC with DLA demonstrates the company's established capability to fulfill federal pharmaceutical requirements and its role as a critical vendor supporting military healthcare programs, the Defense Health Agency, and other government healthcare systems through a flexible contract structure designed to accommodate diverse federal medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.5k | 7/14/25 |